152 related articles for article (PubMed ID: 18460899)
61. Selective activation of α7 nicotinic acetylcholine receptor (nAChRα7) inhibits muscular degeneration in mdx dystrophic mice.
Leite PE; Gandía L; de Pascual R; Nanclares C; Colmena I; Santos WC; Lagrota-Candido J; Quirico-Santos T
Brain Res; 2014 Jul; 1573():27-36. PubMed ID: 24833065
[TBL] [Abstract][Full Text] [Related]
62. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
[TBL] [Abstract][Full Text] [Related]
63. AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy.
Abou-Samra M; Selvais CM; Boursereau R; Lecompte S; Noel L; Brichard SM
J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):518-533. PubMed ID: 31965757
[TBL] [Abstract][Full Text] [Related]
64. Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice.
Kumar A; Bhatnagar S; Kumar A
Am J Pathol; 2010 Jul; 177(1):248-60. PubMed ID: 20472898
[TBL] [Abstract][Full Text] [Related]
65. Trilobatin contributes to the improvement of myopathy in a mouse model of Duchenne muscular dystrophy.
Hermes TA; Fratini P; Nascimento BG; Ferreira LL; Petri G; Fonseca FLA; Carvalho AAS; Feder D
Int J Exp Pathol; 2024 Apr; 105(2):75-85. PubMed ID: 38477495
[TBL] [Abstract][Full Text] [Related]
66. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
Bronisz-Budzyńska I; Chwalenia K; Mucha O; Podkalicka P; Karolina-Bukowska-Strakova ; Józkowicz A; Łoboda A; Kozakowska M; Dulak J
Skelet Muscle; 2019 Aug; 9(1):22. PubMed ID: 31412923
[TBL] [Abstract][Full Text] [Related]
67. Tempol treatment shows phenotype improvement in mdx mice.
Hermes TA; Mâncio RD; Macedo AB; Mizobuti DS; Rocha GLD; Cagnon VHA; Minatel E
PLoS One; 2019; 14(4):e0215590. PubMed ID: 31009514
[TBL] [Abstract][Full Text] [Related]
68. Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-β1/TAK1 signaling pathway.
Xu DQ; Zhao L; Li SJ; Huang XF; Li CJ; Sun LX; Li XH; Zhang LY; Jiang ZZ
Acta Pharmacol Sin; 2021 Jul; 42(7):1080-1089. PubMed ID: 32939036
[TBL] [Abstract][Full Text] [Related]
69. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy.
Villalta SA; Nguyen HX; Deng B; Gotoh T; Tidball JG
Hum Mol Genet; 2009 Feb; 18(3):482-96. PubMed ID: 18996917
[TBL] [Abstract][Full Text] [Related]
70. Bowman-Birk inhibitor attenuates dystrophic pathology in mdx mice.
Morris CA; Selsby JT; Morris LD; Pendrak K; Sweeney HL
J Appl Physiol (1985); 2010 Nov; 109(5):1492-9. PubMed ID: 20847128
[TBL] [Abstract][Full Text] [Related]
71. Nuclear magnetic resonance spectroscopy study of muscle growth, mdx dystrophy and glucocorticoid treatments: correlation with repair.
McIntosh L; Granberg KE; Brière KM; Anderson JE
NMR Biomed; 1998 Feb; 11(1):1-10. PubMed ID: 9608583
[TBL] [Abstract][Full Text] [Related]
72. Expression patterns of regulatory RNAs, including lncRNAs and tRNAs, during postnatal growth of normal and dystrophic (mdx) mouse muscles, and their response to taurine treatment.
Butchart LC; Terrill JR; Rossetti G; White R; Filipovska A; Grounds MD
Int J Biochem Cell Biol; 2018 Jun; 99():52-63. PubMed ID: 29578051
[TBL] [Abstract][Full Text] [Related]
73. Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice.
Spaulding HR; Quindry T; Hammer K; Quindry JC; Selsby JT
J Appl Physiol (1985); 2019 Oct; 127(4):1058-1066. PubMed ID: 31295065
[TBL] [Abstract][Full Text] [Related]
74. l-Glutamine administration reduces oxidized glutathione and MAP kinase signaling in dystrophic muscle of mdx mice.
Mok E; Constantin B; Favreau F; Neveux N; Magaud C; Delwail A; Hankard R
Pediatr Res; 2008 Mar; 63(3):268-73. PubMed ID: 18287965
[TBL] [Abstract][Full Text] [Related]
75. AAV-based shRNA silencing of NF-κB ameliorates muscle pathologies in mdx mice.
Yang Q; Tang Y; Imbrogno K; Lu A; Proto JD; Chen A; Guo F; Fu FH; Huard J; Wang B
Gene Ther; 2012 Dec; 19(12):1196-204. PubMed ID: 22278411
[TBL] [Abstract][Full Text] [Related]
76. Altered ROS production, NF-κB activation and interleukin-6 gene expression induced by electrical stimulation in dystrophic mdx skeletal muscle cells.
Henríquez-Olguín C; Altamirano F; Valladares D; López JR; Allen PD; Jaimovich E
Biochim Biophys Acta; 2015 Jul; 1852(7):1410-9. PubMed ID: 25857619
[TBL] [Abstract][Full Text] [Related]
77. Effects of PDE5 inhibition on dystrophic muscle following an acute bout of downhill running and endurance training.
Batra A; Vohra RS; Chrzanowski SM; Hammers DW; Lott DJ; Vandenborne K; Walter GA; Forbes SC
J Appl Physiol (1985); 2019 Jun; 126(6):1737-1745. PubMed ID: 30946638
[TBL] [Abstract][Full Text] [Related]
78. Nodakenin suppresses lipopolysaccharide-induced inflammatory responses in macrophage cells by inhibiting tumor necrosis factor receptor-associated factor 6 and nuclear factor-κB pathways and protects mice from lethal endotoxin shock.
Rim HK; Cho W; Sung SH; Lee KT
J Pharmacol Exp Ther; 2012 Sep; 342(3):654-64. PubMed ID: 22637723
[TBL] [Abstract][Full Text] [Related]
79. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
[TBL] [Abstract][Full Text] [Related]
80. Imatinib mesylate ameliorates the dystrophic phenotype in exercised mdx mice.
Bizario JC; Cerri DG; Rodrigues LC; Oliveira GL; Nomizo A; de Araujo DD; Fukuhara PS; Ribeiro JC; de Castro FA; Costa MC
J Neuroimmunol; 2009 Jul; 212(1-2):93-101. PubMed ID: 19508953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
